Compare DNOW & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | MLYS |
|---|---|---|
| Founded | 1862 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2014 | 2023 |
| Metric | DNOW | MLYS |
|---|---|---|
| Price | $13.21 | $27.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $16.67 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 3.1M | 889.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $69.47 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $12.59 |
| 52 Week High | $17.26 | $47.65 |
| Indicator | DNOW | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 47.83 |
| Support Level | $13.05 | $26.01 |
| Resistance Level | $13.96 | $31.12 |
| Average True Range (ATR) | 0.43 | 1.62 |
| MACD | -0.04 | -0.29 |
| Stochastic Oscillator | 48.09 | 32.95 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.